The Structural Genomics Consortium at the University of North Carolina at Chapel Hill (SGC - UNC), in partnership with the DiscoverX Corporation, has reached the milestone
halfway point in its development of the Kinase Chemogenomic Set, a potent group of inhibitors which allow deeper exploration of the human kinome, a family of enzymes critical to understanding human disease and developing new therapies.